Synthetic antibodies as therapeutics.

Abstract:

:Synthetic antibody libraries, whose repertoires are designed, have advanced in the last decade to rival natural repertoire-based libraries. Many types of diversity design have been shown to generate highly functional libraries. Defined template and defined diversity in synthetic antibody libraries improve the process of discovering and optimizing new antibodies. Synthetic libraries with different diversity design have targeted different epitopes on antigens, including epitopes that are unlikely to be targeted by immunization and hybridoma. Cross-species binding antibodies are prime examples of products generated by synthetic antibody libraries, and they are becoming the tools of choice to validate the selection of targeted molecules in therapeutic development. Synthetic antibody libraries complement the existing natural repertoire-based antibody libraries and hybridoma approach to maximize the potentials of antibodies as therapeutics.

journal_name

Expert Opin Biol Ther

authors

Fuh G

doi

10.1517/14712598.7.1.73

subject

Has Abstract

pub_date

2007-01-01 00:00:00

pages

73-87

issue

1

eissn

1471-2598

issn

1744-7682

journal_volume

7

pub_type

杂志文章,评审
  • Hypoxia and adipose-derived stem cell-based tissue regeneration and engineering.

    abstract:INTRODUCTION:Realization that oxygen is one of the key regulators of development and differentiation has a profound significance on how current cell-based and tissue engineering applications using adipose-derived stem cells (ASCs) can be further improved. AREAS COVERED:The article provides an overview of mechanisms of...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.2011.570258

    authors: Zachar V,Duroux M,Emmersen J,Rasmussen JG,Pennisi CP,Yang S,Fink T

    更新日期:2011-06-01 00:00:00

  • The immune microenvironment in vulvar (pre)cancer: review of literature and implications for immunotherapy.

    abstract:INTRODUCTION:Vulvar squamous cell carcinoma (VSCC) develops via two different pathways: TP53 mutations in a background of lichen sclerosus or a persistent infection with high-risk human papilloma virus (HPV). The latter group of tumor responds better to treatment than the non-virally induced VSCC. This may be explained...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14712598.2018.1542426

    authors: Abdulrahman Z,Kortekaas KE,De Vos Van Steenwijk PJ,Van Der Burg SH,Van Poelgeest MI

    更新日期:2018-12-01 00:00:00

  • Therapeutic uses of botulinum toxin: from facial palsy to autonomic disorders.

    abstract:BACKGROUND:The therapeutic uses of botulinum toxin have been expanding due to deeper knowledge of its molecular behaviour and different mechanisms of action. OBJECTIVE:To present suggested doses of Botox and Dysport for controlling the muscle hyperkinetic activity in facial palsy in the perioral area and to review oth...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.8.6.791

    authors: de Maio M

    更新日期:2008-06-01 00:00:00

  • Arming oncolytic viruses to leverage antitumor immunity.

    abstract:INTRODUCTION:Over the past decade, the cytolytic capabilities of oncolytic viruses (OVs), exploited to selectively eliminate neoplastic cells, have become secondary to their use to elicit a tumor-directed immune response. AREAS COVERED:Here, based on an NCBI-PubMed literature survey, we review the efforts undertaken t...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.2015.1044433

    authors: de Gruijl TD,Janssen AB,van Beusechem VW

    更新日期:2015-07-01 00:00:00

  • The immunological challenges of malaria vaccine development.

    abstract::Malaria remains an important public health problem throughout the tropical world causing immense human suffering and impeding economic development. Despite extensive research for > 100 years, options for preventing malaria remain limited to vector control and chemoprophylaxis. The complexity of the organism and its li...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.7.12.1841

    authors: Wipasa J,Riley EM

    更新日期:2007-12-01 00:00:00

  • Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.

    abstract:INTRODUCTION:Type 1 diabetes (T1DM) is an immune-mediated disease induced by antigen-specific T cells infiltrating pancreatic beta cells leading to the progressive loss of endogenous insulin secretion. AREAS COVERED:The identification of specific components of the autoimmune response favoured the implementation of sev...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14712598.2016.1180363

    authors: Guglielmi C,Williams SR,Del Toro R,Pozzilli P

    更新日期:2016-06-01 00:00:00

  • Advances in the development of therapeutic nucleic acids against cervical cancer.

    abstract::Cervical cancer is the second most common neoplastic disease affecting women worldwide. Basic, clinical and epidemiological analyses indicate that expression of high-risk human papillomaviruses (HPVs) E6/E7 genes is the primary cause of cervical cancer and represent ideal targets for the application of therapeutic nuc...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.4.8.1251

    authors: DiPaolo JA,Alvarez-Salas LM

    更新日期:2004-08-01 00:00:00

  • Selected application of peptide molecules as pharmaceutical agents and in cosmeceuticals.

    abstract::Introduction: Peptide molecules are being vastly investigated as an emerging class of therapeutic molecules in recent years. Currently, 60 peptides have been approved by the US Food and Drug Administration (FDA), and more would enter the market in near future. Peptides have already opened their ways into cosmeceutical...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14712598.2019.1652592

    authors: Negahdaripour M,Owji H,Eslami M,Zamani M,Vakili B,Sabetian S,Nezafat N,Ghasemi Y

    更新日期:2019-12-01 00:00:00

  • Current views on interferon therapy for HIV.

    abstract:INTRODUCTION:Knowledge of IFN-antiviral activity against HIV infection dates from the first years of the AIDS epidemic. Recombinant IFN had an inhibitory effect on HIV and was not toxic to peripheral blood mononuclear cells (PBMC), and this finding was the basis for the design of clinical trials that evaluated the pote...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14712598.2016.1196180

    authors: Rivero-Juárez A,Frias M,Rivero A

    更新日期:2016-09-01 00:00:00

  • Human stem cell grafts as therapies for motor neuron disease.

    abstract::Stem cell transplantation, a widely accepted therapeutic approach to diseases of modular organs such as the heart and the endocrine pancreas, remains a controversial option for the nervous system. However, historical advances in the 1990s on key aspects of neural plasticity and the appreciation of the selective vulner...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.8.2.137

    authors: Koliatsos VE,Xu L,Yan J

    更新日期:2008-02-01 00:00:00

  • Targeting B cells with biologics in systemic lupus erythematosus.

    abstract:IMPORTANCE OF THE FIELD:The use of biologics as immune modulators in several autoimmune diseases has provided new tools to the physician's therapeutic armamentiarium and has led to improved patients' outcomes and quality of life. By producing autoantibodies, B cells in systemic lupus erythematosus (SLE) are key players...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.2010.524923

    authors: La Cava A

    更新日期:2010-11-01 00:00:00

  • Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer.

    abstract:INTRODUCTION:Regulatory T cells (Tregs) have been characterised in different cancers. They accumulate in peripheral blood and tumour microenvironments where they suppress tumour-specific immune responses, enabling tumours to develop without challenge. This tumour immune evasion represents a major obstacle to successful...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.2014.900539

    authors: Chaudhary B,Abd Al Samid M,al-Ramadi BK,Elkord E

    更新日期:2014-07-01 00:00:00

  • Hydrogels for oral delivery of therapeutic proteins.

    abstract::In recent years there has been significant new interest in the development of transmucosal (mostly oral) pharmaceutical formulations for the delivery of therapeutic proteins. Emphasis has been given to the molecular design of new carriers for the delivery of insulin, calcitonin and various types of interferons for the...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.4.6.881

    authors: Peppas NA,Wood KM,Blanchette JO

    更新日期:2004-06-01 00:00:00

  • Tocilizumab for treating juvenile idiopathic arthritis.

    abstract:INTRODUCTION:Based on the known relevance of IL-6 in juvenile idiopathic arthritis (JIA) pathophysiology, tocilizumab has been investigated and approved for use in the treatment of systemic and polyarticular JIA. Tocilizumab is a humanized monoclonal antibody that inhibits signaling through both membrane bound and solu...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.2016.1150997

    authors: Turnier JL,Brunner HI

    更新日期:2016-01-01 00:00:00

  • Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases.

    abstract::Introduction: The expiry of patents for biologics has led to the introduction of biosimilars for the treatment of immune-mediated inflammatory diseases (IMIDs). These treatment alternatives may allow earlier and wider access to appropriate therapy for patients without increasing the economic burden on health-care syst...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14712598.2019.1610381

    authors: Edwards CJ,Hercogová J,Albrand H,Amiot A

    更新日期:2019-10-01 00:00:00

  • The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.

    abstract:BACKGROUND:Obesity has long been associated with psoriasis and it is considered to be an independent risk factor for chronic heart diseases in these patients. Recently, some of the biologic drugs used for psoriasis have been reported to cause increase in body weight. It is currently not clear if this increased body wei...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/14712598.2014.900541

    authors: Al-Mutairi N,Nour T

    更新日期:2014-06-01 00:00:00

  • Probiotics as oral health biotherapeutics.

    abstract:INTRODUCTION:Oral health is affected by its resident microorganisms. Three prominent oral disorders are dental caries, gingivitis and periodontitis, with the oral microbiota playing a key role in the initiation/progression of all three. Understanding the microbiota and the diseases they may cause is critical to the dev...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.2012.693474

    authors: Saha S,Tomaro-Duchesneau C,Tabrizian M,Prakash S

    更新日期:2012-09-01 00:00:00

  • Rationale for and clinical development of anti-fractalkine antibody in rheumatic diseases.

    abstract::Introduction: Rheumatic diseases are inflammatory diseases that damage target organs via multiple subsets of immune cells. Fractalkine (FKN) acts as chemoattractant as well as adhesion molecule. It contributes to the pathogenesis of rheumatoid arthritis (RA) and other rheumatic diseases through multiple mechanisms: th...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章

    doi:10.1080/14712598.2020.1764931

    authors: Muraoka S,Nishio J,Kuboi Y,Imai T,Nanki T

    更新日期:2020-11-01 00:00:00

  • Engineered BDNF producing cells as a potential treatment for neurologic disease.

    abstract:INTRODUCTION:Brain-derived neurotrophic factor (BDNF) has been implicated in wide range of neurological diseases and injury. This neurotrophic factor is vital for neuronal health, survival, and synaptic connectivity. Many therapies focus on the restoration or enhancement of BDNF following injury or disease progression....

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14712598.2016.1183641

    authors: Deng P,Anderson JD,Yu AS,Annett G,Fink KD,Nolta JA

    更新日期:2016-08-01 00:00:00

  • Biological therapies for psoriasis.

    abstract:INTRODUCTION:Biological therapies have revolutionized moderate-to-severe psoriasis treatment. Increased understanding of disease pathogenesis has yielded multiple therapeutic targets involving the IL-23/Th17 pathway, while current therapies continue to be monitored for long-term efficacy and safety. AREAS COVERED:This...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.2013.853739

    authors: Mansouri B,Patel M,Menter A

    更新日期:2013-12-01 00:00:00

  • Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study.

    abstract::ABSTRACT Background: Thymosin alpha-1 (Ta-1) suppresses HBV viral replication, while the evidence of combination effect with nucleoide is still limited. We aimed to investigate the efficacy and safety of combination therapy of Ta-1 with entecavir (ETV) in patients with compensated liver cirrhosis. RESEARCH DESIGN AND...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1080/14712598.2018.1451511

    authors: Wu X,Shi Y,Zhou J,Sun Y,Piao H,Jiang W,Ma A,Chen Y,Xu M,Xie W,Cheng J,Xie S,Shang J,Cheng J,Xie Q,Ding H,Zhang X,Bai L,Zhang M,Wang B,Chen S,Ma H,Ou X,Jia J,You H

    更新日期:2018-07-01 00:00:00

  • Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future.

    abstract::Complete resection is mandatory in order to achieve a cure in patients with early-stage non-small cell lung cancer (NSCLC). However, despite complete resection, a substantial proportion of patients have disease recurrence, with distant metastases being the primary sites of failure. Recent trials have conclusively demo...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.6.7.709

    authors: Potti A,Ganti AK

    更新日期:2006-07-01 00:00:00

  • Interleukin-21: biology and application to cancer therapy.

    abstract:BACKGROUND:IL-21, a recently described common gamma-chain cytokine, can induce the maturation and enhanced cytotoxicity of natural killer (NK) and CD8(+) T cells and proliferation of CD40-stimulated B cells. Exogenous IL-21 has antitumor effects in murine models via immunological mechanisms. In addition, IL-21 can also...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.8.9.1295

    authors: Andorsky DJ,Timmerman JM

    更新日期:2008-09-01 00:00:00

  • Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?

    abstract:INTRODUCTION:Two humanized monoclonal antibodies, bapineuzumab and solanezumab, directed against the N terminus and mid-region of β-amyloid (Aβ), respectively, were recently tested in large, long-term Phase III trials in patients with mild-to-moderate Alzheimer's disease (AD). AREAS COVERED:This review discusses curre...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.2014.935332

    authors: Panza F,Solfrizzi V,Imbimbo BP,Logroscino G

    更新日期:2014-10-01 00:00:00

  • Haematopoietic stem and progenitor cell-targeted therapies for thrombocytopenia.

    abstract::This review discusses the present outlook for new thrombocytopenia therapies that induce haematopoietic stem and progenitor cells to proliferate, differentiate and produce functional platelets. A brief overview of megakaryopoiesis and its regulation by thrombopoietin (TPO) is followed by a discussion of how early expe...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.6.10.983

    authors: Szilvassy SJ

    更新日期:2006-10-01 00:00:00

  • Rituximab preserves vision in ocular mucous membrane pemphigoid.

    abstract:OBJECTIVE:To study the effectiveness and safety of anti-CD20 B-cell antibody rituximab (RTX) in the treatment of ocular mucous membrane pemphigoid (MMP). METHODS:Retrospective analysis of six MMP patients receiving RTX with or without concomitant immunosuppression. RTX was administered as a high dose regimen (1000 mg/...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章

    doi:10.1517/14712598.2015.1046833

    authors: Rübsam A,Stefaniak R,Worm M,Pleyer U

    更新日期:2015-07-01 00:00:00

  • How could we have better vaccines against tuberculosis?

    abstract:BACKGROUND:Tuberculosis (TB), an infirmity that mainly affects the respiratory system, is the world's second deadliest infectious disease, with > 9 million new cases diagnosed in 2006. One-third of the world's population is now infected with the TB bacillus. According to the WHO, an estimated 1.7 million people died fr...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.8.11.1759

    authors: Giri PK

    更新日期:2008-11-01 00:00:00

  • Cancer immunotherapy and heat-shock proteins: promises and challenges.

    abstract::Recent mechanistic studies on the role of heat-shock proteins (HSPs) to induce innate and adaptive immune responses have resulted in conflicting reports. Whereas some groups reported that HSPs have direct immunological function, others emphasised the endotoxin contamination of HSP preparations and questioned the antig...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.4.3.363

    authors: Manjili MH,Wang XY,MacDonald IJ,Arnouk H,Yang GY,Pritchard MT,Subjeck JR

    更新日期:2004-03-01 00:00:00

  • Prospects and RISC score of viral gene therapy for sarcoma.

    abstract::Soft tissue sarcomas are a challenge for medical oncology and gene therapy. Protective and sensitising approaches that target normal and malignant tissue, respectively, both have their role for opening the therapeutic window. Recent data show that an intensive maintenance chemotherapy significantly reduces metastatic ...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.3.8.1241

    authors: Fruehauf S,Veldwijk MR,Zeller WJ,Laufs S

    更新日期:2003-12-01 00:00:00

  • Tissue engineering strategies for in vivo neovascularisation.

    abstract::Neovascularisation is a promising alternative therapeutic approach to re-establish blood flow in ischaemic tissues of patients suffering from coronary artery or peripheral artery disease. Often, these patients are not suitable candidates for current revascularisation procedures such as coronary angioplasty or bypass s...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审

    doi:10.1517/14712598.2.8.805

    authors: Ennett AB,Mooney DJ

    更新日期:2002-12-01 00:00:00